(4R)-4-ethyl-1,3-oxazolidin-2-one → (R)-3-{5-[4-(4-chlorobenzoyl)piperidine-1-carbonyl]pyridin-2-yl}-4-ethyloxazolidin-2-one

HRID 1803970노트

반응식

HRID 1803970 반응식
Br[C:2]1[N:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([C:16](=[O:24])[C:17]3[CH:22]=[CH:21][C:20]([Cl:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1.[CH2:25]([C@@H:27]1[CH2:31][O:30][C:29](=[O:32])[NH:28]1)[CH3:26]>>[Cl:23][C:20]1[CH:21]=[CH:22][C:17]([C:16]([CH:13]2[CH2:14][CH2:15][N:10]([C:8]([C:5]3[CH:4]=[CH:3][C:2]([N:28]4[C@H:27]([CH2:25][CH3:26])[CH2:31][O:30][C:29]4=[O:32])=[N:7][CH:6]=3)=[O:9])[CH2:11][CH2:12]2)=[O:24])=[CH:18][CH:19]=1

참가 물질

3

반응물 2

HCID 641503(4R)-4-ethyl-1,3-oxazolidin-2-oneHCID 58484839(6-Bromopyridin-3-yl)[4-(4-chlorobenzoyl)piperidin-1-yl]methanone

생성물 1

HCID 54755118(R)-3-{5-[4-(4-chlorobenzoyl)piperidine-1-carbonyl]pyridin-2-yl}-4-ethyloxazolidin-2-one수율 61.7%

실험 절차

By reaction and treatment in the same manner as in Preparation Example 31 and using (6-bromopyridin-3-yl)[4-(4-chlorobenzoyl)piperidin-1-yl]methanone (2 g) described in Preparation Example 23 and (R)-4-ethyloxazolidin-2-one (300 mg) described in Preparation Example 26, the title compound (710 mg) was obtained.

후처리

  1. customBy reaction and treatment in the same manner
  2. customas in Preparation Example 31
  3. customdescribed in Preparation Example 26

출처 및 근거

ORD 기록
ord-efb87ac04d4b4ee1b8144dbfbafc1b6e
출처 데이터셋
uspto-grants-2013_01
특허 번호
US08354401B2

반응 노트

불러오는 중…